Day: March 14, 2023

Washington Water Service Finalizes Acquisition of Bethel Greenacres Water Association

Washington Water Service Finalizes Acquisition of Bethel Greenacres Water Association

GIG HARBOR, Wash., March 14, 2023 (GLOBE NEWSWIRE) — Following approval by the Washington Utilities and Transportation Commission (WUTC) in February 2023, Washington Water Service (Washington Water)—a subsidiary of California Water Service Group (Group)—has closed the acquisition of Bethel Greenacres Water Association’s water system assets. The Bethel Greenacres system includes 200 residential customer connections in Graham, Wash., adjacent to Washington Water’s East Pierce system. Washington Water has been serving Bethel Greenacres customers through an operation and maintenance agreement since September 2022. The utility plans to continue investing in the Bethel Greenacres system to support the provision of safe, reliable water service to its customers for their everyday and emergency needs, both now and in the future. “We appreciate...

Continue reading

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Advancing IND-enabling activities for lead program in diabetes, SIG-002, with plans to conduct non-human primate studies in second half of 2023 SIG-002 demonstrated efficacy and durability in in vivo mouse models for up to 17 weeks Extended anticipated cash runway into 2025 CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quarter and year ended December 31, 2022 as well as certain other business highlights. “Reflecting on 2022, we made many important strategic decisions that will help shape the future of our Company, including conducting research that informed the optimization of our SLTx platform,...

Continue reading

Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

Conference Call and Webcast to be Held at 2:00 P.M CET/8:00 A.M. EDT on March 29, 2023   PARIS and CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announces that it will provide an operational update and report its financial results for full-year ending December 31, 2022, on Tuesday, March 28, 2023, after the close of the US market. This release will be followed by a conference call and live audio webcast on Wednesday, March 29, 2023, at 2:00 PM CET/8:00 AM EDT, prior to the open of the US market. During the call, Laurent Levy, chief executive officer, and Bart Van Rhijn, chief financial officer, will briefly review the...

Continue reading

PFSweb Reports Strong Fourth Quarter and Full Year 2022 Results

PFSweb Reports Strong Fourth Quarter and Full Year 2022 Results

Demonstrates Strong 2022 Results and Continued Momentum Into 2023, Backed by Record Annual Sales Bookings and Order Fulfillment Performance Full Year 2023 Guidance of Annual Service Fee Revenue Growth of 5% to 10% IRVING, Texas, March 14, 2023 (GLOBE NEWSWIRE) — PFSweb, Inc. (NASDAQ: PFSW) (the “Company”) is reporting results for the fourth quarter and full year ended December 31, 2022. “2022 was a strong year for PFS as we leveraged ongoing tailwinds in the eCommerce industry,” said Mike Willoughby, CEO of PFSweb. “Across our core verticals, our client brands focusing on premium and luxury goods proved resilient by delivering strong holiday order volumes. These tailwinds and our customized, brand centric operational capabilities helped deliver our previously announced record sales bookings year in 2022, generating...

Continue reading

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

Enrollment in the company’s Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023. The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a Biologics License Application for an accelerated approval in the United States. The company continues to enroll patients in its Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer, head and neck cancer, or bladder cancer. The company anticipates reporting additional data from this study over the course of 2023. The company ended 2022 with...

Continue reading

BRT Apartments Corp. Reports Fourth Quarter and Full Year 2022 Results

BRT Apartments Corp. Reports Fourth Quarter and Full Year 2022 Results

– Issues Full Year 2023 Guidance – GREAT NECK, N.Y., March 14, 2023 (GLOBE NEWSWIRE) — BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust that owns, operates, and, to a lesser extent, holds interests in joint ventures that own multi-family properties, today reported results for the fourth quarter and year ended December 31, 2022, and issued guidance for expected full year 2023 results. Highlights Reported results for the fourth quarter of 2022 of a net loss of $4.2 million, or $(0.22) per diluted share, Funds from Operations, or FFO, of $0.40 per diluted share and Adjusted Funds from Operations, or AFFO, of $0.37 per diluted share. Reported results for 2022 of net income of $50.0 million, or $2.66 per diluted share, FFO of $1.24 per diluted share and AFFO of $1.52 per diluted share. Equity in earnings of unconsolidated...

Continue reading

StoneCo Reports Fourth Quarter and Fiscal Year 2022 Results

StoneCo Reports Fourth Quarter and Fiscal Year 2022 Results

Key 4Q22 metrics exceeded guidance on strength of 2022 execution; Revenue of R$2.7 billion, + 44% y/y (vs R$2.6+ billion guidance); Adj. EBT of R$316 million, +50% q/q (vs R$250+ million guidance); MSMB TPV of R$81.9 billion, +23% year over year (vs R$78.0 – R$79.0 billion guidance) GEORGE TOWN, Grand Cayman, March 14, 2023 (GLOBE NEWSWIRE) — StoneCo Ltd. (Nasdaq: STNE) (“Stone” or the “Company”) today reports its financial results for its fourth quarter and fiscal year ended December 31, 2022. “Dear Shareholders, This quarter, I would like to highlight our evolution along 2022. As I transition to the board role and hand the executive leadership to Pedro, I also want to reflect back on what I think makes your company great and what I believe will be the foundation for its success over the next decades. I think 2022 was a...

Continue reading

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Ongoing with Data Expected Mid-Year   Continued Progress Across Pipeline of GeneTAC™ Small Molecules with Three Programs Expected to be in Clinical Development in the Next Two Years Strong Financial Position with $330 Million in Cash and Securities Expected to Support Operating Runway through 2025 CARLSBAD, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today highlighted recent progress and anticipated upcoming milestones across its clinical and research-stage pipeline of novel GeneTAC™ small molecules and reported fourth quarter and full year 2022 financial results. “We are very proud of the important progress...

Continue reading

Westrock Coffee Reports Fourth Quarter and Full Year 2022 Results and Provides 2023 Outlook

Westrock Coffee Reports Fourth Quarter and Full Year 2022 Results and Provides 2023 Outlook

Net Sales for the Fourth Quarter and Full Year 2022 Increase by 20% and 24%, Respectively Net Loss of $55.5 Million and Adjusted EBITDA of $60.1 Million for the Full Year 2022, Representing Adjusted EBITDA Growth of 27% Strategic Acquisition of West Coast-Based Bixby Coffee Expands Influencer Marketing Sales Channel Adjusted EBITDA Expected to Grow 10% to 25% in Fiscal 2023 LITTLE ROCK, Ark., March 14, 2023 (GLOBE NEWSWIRE) — Westrock Coffee Company (Nasdaq: WEST) (“Westrock Coffee” or “the Company”) today reported financial results for the fourth quarter and full year 2022. Scott T. Ford, CEO and Co-founder, stated, “We are pleased to announce strong growth in net sales, gross profit and Adjusted EBITDA for full year 2022. I am very grateful to the team for their near heroic efforts that delivered record annual results, even...

Continue reading

Casa Systems Announces CEO Transition and Reports Fourth Quarter and Full Year 2022 Financial Results

Casa Systems Announces CEO Transition and Reports Fourth Quarter and Full Year 2022 Financial Results

Jerry Guo to Retire as President and CEO, Remains on Casa Board of DirectorsBruce Evans Appointed New Chairman of Expanded Board of DirectorsScott Bruckner Joins the Board of Directors Q4 Revenue of $84.4 Million Slightly Exceeds High End of Preliminary Guidance GAAP Net Income of $1.2 Million and Positive Net Adjusted EBITDA of $5.2 Million for Quarter Debt Reduced by $49.2 Million to $226.0 Million during Q4 Provides Full Year Revenue and Net Adjusted EBITDA Guidance ANDOVER, Mass., March 14, 2023 (GLOBE NEWSWIRE) — Casa Systems, Inc. (Nasdaq: CASA), a leading provider of cloud-native software and physical broadband technology solutions for wireless, cable, and fixed networks, today announced that the Company’s President and Chief Executive Officer will be retiring, and reported its financial results for the fourth quarter and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.